Trump announces reforms to accelerate access to psychedelic drug treatments

The Guardian - World News Public HealthNews ReportEN 2 min read 100% complete by Reuters and Guardian staffApril 18, 2026 at 05:03 PM

Part of Story

Trump joined by Joe Rogan as he signs order to speed up psychedelic review

View All Perspectives

Read Original Article

AI Summary

short article 2 min

Donald Trump announced reforms on Saturday aimed at accelerating access to psychedelic drug treatments, specifically directing the FDA to expedite the review of drugs like ibogaine. The executive order intends to pave the way for reclassification of these drugs, which can cause hallucinations and are largely illegal, after successful clinical trials. The US will also dedicate $50 million to federal research into ibogaine, which has shown potential in treating PTSD and substance abuse. The reforms could immediately benefit Texas, which has already invested in ibogaine research. The announcement was made with figures such as the US health secretary, Robert F Kennedy Jr, and Joe Rogan present, all of whom have expressed support for psychedelic research and/or legalization.

Article Analysis

Framing Angle

Public Health

Primary framing

Political Strategy

Secondary framing

Measured

Sensationalism

Factual

Fact vs Opinion

OpinionFactual

Sources Cited

Well sourced

AI-powered analysis of article framing, tone, and source quality. Scores help identify potential bias and information quality.

Key Claims (5)

AI-Extracted

Texas has already committed $50m to studying ibogaine.

factual — The New York Times100% confidence

The US would dedicate $50m to federal research into ibogaine.

factual — Trump100% confidence

US federal officials said that the reforms would pave the way for the drugs to be reclassified after successful clinical trials.

factual — US federal officials100% confidence

The president signed an executive order directing the FDA to expedite review of drugs such as ibogaine.

factual100% confidence

Donald Trump announced reforms to speed up access to medical research and treatment based on psychedelic drugs.

factual100% confidence

Claims are automatically extracted and should be independently verified. Attribution indicates the stated source of the claim.

Key Entities & Roles

Key Player Opposition Context

Joe Rogan 40% New York Times 40% Texas 50% Robert F Kennedy Jr ×250% United States ×270% Ibogaine ×570% Food and Drug Administration (FDA) ×270% Donald Trump ×790%

Keywords

psychedelic drugs 100% ibogaine 90% fda 70% medical research 70% donald trump 70% treatment 60% post-traumatic stress disorder 60% drug reclassification 50% clinical trials 50% substance abuse 40%